Ana de Barros, PhD, managing science editor —

Ana holds a PhD in immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. Ana was awarded two FCT fellowships and has won the Portuguese Immunology Society Best Paper and Best Poster award in 2009 and 2010, as well as the CESPU International Research Award in 2010. After leaving the lab to pursue a career in science communication, she served as the director of science communication at iMM Lisbon.

Articles by Ana de Barros

10 Quotes to Help You When You’re Feeling Down

We know dealing with a condition such as Parkinson’s disease can sometimes feel, both for the patients and the caregivers. You feel like you’re not doing enough or as if the disease is taking up all your time and attention. To help you on your journey, we’ve gathered a few quotes we thought might help…

Difficulty in Diagnosis Greatly Affects Quality of Life of Parkinson’s Patients, Survey Finds

People living with Parkinson’s disease are frustrated with the difficulty in getting an accurate diagnosis, a new Health Union survey found. The “Parkinson’s in America 2017″ survey, conducted online between Jan. 19 and March 13 of this year, includes responses from 1,100 Parkinson’s patients and was released through ParkinsonsDisease.net, Health Union’s newest…

Parkinson’s Vaccine Triggers Solid Immune Response, Phase 1 Clinical Trial Shows

AFFiRiS’s new Parkinson’s vaccine, AFFITOPE PD03A, triggered a solid immune response against the alpha-Synuclein (aSyn) protein associated with the disease, according to a Phase 1 clinical trial. Patients also tolerated the therapy well, researchers said. Werner Poewe, a professor at Austria’s Medical University Insbruck, presented the results at the 21stInternational Congress…

Herantis Pharma Wins U.S. Patent for Therapeutic Use of MANF to Treat Parkinson’s Disease

The U.S. Patent and Trademark Office has granted Finland’s Herantis Pharma a patent covering the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) to treat Parkinson’s disease and other neurological illnesses. The patent is related to a genetic sequence encoding MANF. Molecules such as MANF nucleic acids and MANF polypeptides, can be used…